Harrow, Inc. $HROW Shares Sold by Royce & Associates LP

Royce & Associates LP cut its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 3.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 533,013 shares of the company’s stock after selling 20,680 shares during the quarter. Royce & Associates LP owned about 1.44% of Harrow worth $25,681,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HROW. Raymond James Financial Inc. acquired a new position in shares of Harrow in the second quarter valued at about $48,000. State of Alaska Department of Revenue acquired a new stake in shares of Harrow in the third quarter worth $83,000. Tower Research Capital LLC TRC raised its holdings in shares of Harrow by 345.0% during the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock worth $103,000 after purchasing an additional 2,615 shares during the last quarter. AlphaQuest LLC lifted its position in Harrow by 743.0% during the third quarter. AlphaQuest LLC now owns 3,819 shares of the company’s stock valued at $184,000 after purchasing an additional 3,366 shares during the period. Finally, Independent Advisor Alliance purchased a new stake in Harrow in the third quarter valued at $210,000. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research report on Thursday, January 22nd. Zacks Research cut shares of Harrow from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd. HC Wainwright lifted their price objective on shares of Harrow from $64.00 to $69.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $94.00 price objective on shares of Harrow in a research report on Tuesday, November 11th. Finally, LADENBURG THALM/SH SH raised their target price on Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Harrow presently has an average rating of “Moderate Buy” and an average target price of $71.43.

Harrow Stock Performance

NASDAQ HROW opened at $54.18 on Monday. The company has a market cap of $2.01 billion, a PE ratio of -541.75 and a beta of 0.05. The stock’s 50 day simple moving average is $48.53 and its 200-day simple moving average is $43.70. Harrow, Inc. has a 1-year low of $20.85 and a 1-year high of $54.85. The company has a debt-to-equity ratio of 5.21, a current ratio of 2.72 and a quick ratio of 2.52.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.